Ukraine pip GB to European men's team final gold

Putin Claims Kharkiv: Zelensky's General's Startling Admission Shakes NATO and U.S

Ukraine's intelligence chief, Kirill Budanov, has openly acknowledged the worsening situation in the country, particularly in the north, where Moscow has seized multiple villages in the Kharkiv region. With a shortage of manpower and delays in Western military aid, Ukraine's military is facing a critical situation. Budanov warned that Russia's next incursion is imminent, putting further strain on Ukrainian forces. Despite efforts to redirect troops, the frontline remains precarious, with Budanov expressing concern about the country's defense capabilities. #RussiaKharkivAttack #KharkivInvasion #RussiaAttacksKharkiv #Ukraine #Kharkiv #Frontline #Intel #Putin #Zelensky #NATO #US #Military #Defense #Security #War #Russia #Admission #Crisis ~HT.178~PR.152~ED.103~GR.124~

Blinken visits Ukraine to tout US support for Kyiv's fight against Russia's advances

Blinken reiterates US arms will help Ukraine as it reels from latest Russian attack

As Russia scales-up attacks on Ukraine's north-eastern border, US Secretary of State Antony Blinken reassures Ukrainian president Volodymyr Zelenskyy that soon-to-arrive military aid will help on the front lines.

Biden Signs Bill Banning Russian Uranium Imports

Biden Signs Bill , Banning Russian Uranium Imports. The U.S. president signed the bipartisan bill into law on March 13, 'The Guardian' reports. . The measure is viewed as another avenue of pressure against Vladimir Putin's attack on Ukraine. The measure is viewed as another avenue of pressure against Vladimir Putin's attack on Ukraine. Enriched uranium is used to fuel nuclear power plants. Russia supplies the world with most of it, 'The Guardian' reports. Approximately 24% of the uranium used by nuclear power plants in the U.S. is provided by Russia. The import ban will begin in 90 days. However, the Department of Energy (DOE) will be permitted to issue waivers if supplies run low until 2028. U.S. National Security Adviser Jake Sullivan said the new law will... . ... “strengthen our nation’s energy and economic security by reducing, and ultimately eliminating, our reliance on Russia for civilian nuclear power.”. According to a U.S. House report, one U.S. conversion facility will soon be able to provide about “40% of U.S. market demand in the near term.”. According to a U.S. House report, one U.S. conversion facility will soon be able to provide about “40% of U.S. market demand in the near term.”. Meanwhile, Canada, France, Japan and other countries will help America sustain its uranium supply via an “allied alternative,” said Kathryn Huff, the DOE’s assistant secretary for nuclear

Blinken in Kyiv says US arms will make a difference as Ukraine reels from a new Russian offensive

New Analysis Suggests Long-Term Effectiveness for Wegovy Users

New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users . NBC reports that patients taking Novo Nordisk's obesity treatment maintain an average of 10% weight loss over four years. The news potentially boosts the drugmaker's push for Wegovy to be covered by insurers and governments. . The company submitted long-term findings at the European Congress on Obesity in Venice, Italy. . This is the longest study we’ve conducted so far of semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC. We see that once the majority of the weight loss is accrued, you don’t go back and start to increase in weight if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC. According to another analysis published by the drugmaker, approximately 17% of trial participants stopped using the treatment due to side effects like nausea. . The costly treatment ranges from $200 to nearly $2,000 per month in the ten countries where the drug is available. NBC reports that Novo Nordisk was the first drugmaker to market GLP-1 agonists, originally developed as a diabetes treatment, to address record high obesity rates. NBC reports that Novo Nordisk was the first drugmaker to market GLP-1 agonists, originally developed as a diabetes treatment, to address record high obesity rates. Rival Eli Lilly launched its drug Zepbound in the United States in December of 2023. . Neither drugmaker has managed to produce enough of the treatment to meet surging demand

European Commission chief von der Leyen visits Rome as campaign trail continues

Prior to her Monday meetings with Italian political leaders, von der Leyen was a guest on national TV, where she spoke about the need to defend Ukraine against Russia's aggression to preserve peace in Europe.

Protesters lay mock coffins in Milan over workplace safety in Italy

One of Milan's iconic squares, was filled with symbolic coffins by Italy's second-largest union to highlight the issue of workplace fatalities.